Genomics: Insight

Research Question: How do genetic polymorphisms in the CYP1A2 and ADORA2A genes influence interindividual variability in caffeine metabolism and habitual consumption? 

Introduction:

Caffeine is the most widely consumed psychostimulant globally, primarily ingested through coffee, tea, and soft drinks. While the European Food Safety Authority suggests safe daily limits of 400 mg for adults, actual consumption varies drastically between individuals. This variability is not merely a matter of preference, but is instead rooted in biological mechanisms. Recent genomic research, including genome-wide association studies (GWAS), has identified specific genetic loci that dictate how an individual’s body processes caffeine and how their brain responds to it. Understanding these genomic factors is significant for global health, as caffeine consumption interacts with various physiological states, including sleep, anxiety, and the risk for neurodegenerative diseases. 

Significance: 

The genetic basis of caffeine metabolism carries significant implications for public health and clinical medicine. Caffeine is consumed by approximately 90% of adults worldwide (Nehlig, 2018), yet it is among the least regulated psychoactive substances available, sold without age restrictions in concentrations exceeding 200 mg per serving. A polymorphism, a variation in DNA sequence, in CYP1A2 (rs762551) divides the population into “fast” and “slow” metabolizers. As noted by Guest et al. (2018), individuals categorized as “slow” metabolizers (those with the AC or CC genotype) have been shown to have an elevated risk of myocardial infarction and hypertension with increasing caffeine consumption.

Polymorphisms in ADORA2A control individual sensitivity to caffeine; certain genotypes are associated with increased caffeine-induced anxiety and negative impacts on sleep (Nehlig, 2018). Recognizing these genetic differences may guide clinicians toward more personalized caffeine guidance, and regulators toward improved safety labeling.

Analysis: 

Pharmacokinetics and Absorption of Caffeine:

In a 2018 study, Nehlig established that caffeine is characterized by its metabolic efficiency; once ingested, it is rapidly absorbed by the gastrointestinal tract, with 99% of the compound taken up within just 45 minutes. While about 20% of this absorption happens in the stomach, the majority occurs in the small intestine. For a healthy adult, plasma caffeine typically reaches its peak in approximately 30 minutes. However, how caffeine is ingested matters; caffeine from coffee, tea or capsules hits this peak quickly, whereas the acidic pH of cola and chocolate delay that peak to between 1.5 to 2 hours. Once in the bloodstream, caffeine’s lipophilic nature allows it to cross all biological membranes, including the blood-brain barrier and placental barrier (Nehlig, 2018, pp. 386-387).

The Role of CYP1A2 in Metabolism:

The liver is the primary engine for clearing caffeine from the body. This process relies almost entirely on a specific enzyme called CYP1A2, which is responsible for over 95% of caffeine metabolism (Guest et al., 2018).Through a series of chemical reactions known as demethylation, the liver breaks caffeine down into three main active metabolites: paraxanthine (84%), theobromine (12%), and theophylline (4%). Of these three metabolites, paraxanthine is particularly significant because it is just as potent as caffeine for the blockage of adenosine receptors. (Nehlig, 2018).

The CYP1A2 gene’s activity is largely explained by a polymorphism at position 163 (rs762551), where an A to C substitution decreases enzyme inducibility. Individuals with the AA genotype are “fast metabolizers”, representing 46% of the population. In contrast, carriers of the C-allele are “slow metabolizers” who show higher plasma caffeine levels after ingestion and represent 54% of the population (Nehlig, 2018).

This distinction is clinically relevant because slow metabolizers are more prone to experiencing caffeine-induced anxiety, sleep disturbances, and elevated blood pressure (Guest et al., 2018; Nehlig, 2018). Furthermore, research indicates that fast metabolizers generally have a higher habitual coffee intake compared to slow metabolizers, likely because they clear the stimulant quickly and require more frequent consumption to maintain its effects (Denden et al., 2016).

Role of ADORA2A in Neurological Response:

As noted by Nehlig (2018), while CYP1A2 regulates how long caffeine stays in the system, the ADORA2A gene dictates the brain’s sensitivity to it. Caffeine acts as an antagonist to adenosine receptors, which normally promote sleep and relaxation.  A specific C-to-T substitution at nucleotide position 1083 (rs5751876) in ADORA2A is associated with an individual's sensitivity to caffeine’s effects on sleep and caffeine-induced anxiety. Research suggests that individuals may adjust their habitual caffeine consumption based on these genetic predispositions to avoid negative side effects like insomnia or anxiety (Retey et al., 2007).

Gene-Environment Interactions:

Beyond genetics, several environmental and lifestyle factors alter how an individual processes caffeine, creating a complex interplay between biology and behavior. For instance, cigarette smoking has been shown to almost double the rate of caffeine metabolism because polycyclic aromatic hydrocarbons in smoke induce the activity of hepatic enzymes, specifically CYP1A2 (Nehlig, 2018). The presence of liver disease can have an opposite effect; because the liver is the primary site of metabolism, conditions such as cirrhosis, or hepatitis B, or hepatitis C drastically reduce caffeine clearance, reflecting the delay in synthesis of paraxanthine (Nehlig, 2018).

Dietary choices and pharmacological interactions further complicate this metabolic picture. Certain dietary foods and beverages with acidic pH can delay the initial absorption of the compound, while the co-ingestion of alcohol with caffeine may influence subjective experiences and lead to problems with behavioral regulation (Garcia et al., 2025). Furthermore, many medications, particularly psychiatric drugs like certain antidepressants and antipsychotics, are metabolized by the same CYP1A2 pathway. This can lead to competitive inhibition, potentially increasing drug concentrations to toxic levels (Nehlig, 2018).

Recognizing that each individual operates under a unique genetic “blueprint” allows for a shift toward precision medicine, where dietary guidelines are designed to the individual’s DNA.

Beyond daily habits, these genetic predispositions have a high impact on human performance, especially when it comes to sports and athletics. According to the 2018 study conducted by Guest et al., caffeine is a well-known ergogenic aid used by competitive athletes to improve endurance and reduce perceived exertion; however, its efficiency is highly dependent on the CYP1A2 genotype. The same research suggests that “fast metabolizers” (AA genotype) typically experience the greatest performance gains, since their systems efficiently convert caffeine into paraxanthine, a potent stimulant.

As genomics becomes more accessible, the roles of dietitians and geneticists are evolving to incorporate Nutrigenomics. This field allows practitioners to move away from generic guidelines and provide advice based on the fact that each individual operates differently at a molecular level.

Critical Analysis of Current Research:

While the correlation between the CYP1A2 genotype and caffeine metabolism is well-established, the current body of research faces significant constraints that require cautious interpretation of results. A primary concern is the potential for population bias; much of the genome-wide association study (GWAS) data and specific genotype performance trials, such as those by Guest et al., focus on a specific demographic groups, which may not reflect the genetic diversity of global populations. Furthermore, many studies rely heavily on self-reported caffeine intake, a method that is susceptible to inaccuracies regarding memory bias and the precise concentration of caffeine in different types of beverages.

The complex relationship between biology and behavior is often interfered with by environmental variables that are difficult to isolate. Factors such as sleep quality, psychological stress, and dietary patterns (including the consumption of acidic foods), can significantly alter metabolic rates independently of the CYP1A2 genotype (Nehlig, 2018). Future research must prioritize standardized metabolic testing over self-reporting and include more diverse groups to strengthen the evidence base for conclusions.

Conclusion: 

This review demonstrates that interindividual variability in caffeine response is fundamentally driven by genetic polymorphisms in CYP1A2 and ADORA2A genes. To address the research question, the analysis focused primarily on the comprehensive 2018 review by Nehlig, which provided the mechanistic evidence necessary to link these specific genotypes to behavioral outcomes. Specifically, the rs762551 polymorphism in CYP1A2 determines metabolic speed, where fast (AA) metabolizers clear caffeine rapidly and often require higher habitual intake to maintain its effects, while “slow”(C-allele) metabolizers face increased risks of caffeine-induced anxiety, disrupted sleep and cardiovascular strain. Simultaneously, the rs5751876 polymorphism in ADORA2A dictates individual sensitivity to caffeine, explaining why certain individuals experience acute anxiety or insomnia even at low doses (Retey et al., 2007).

While these genetic factors provide a biological “blueprint” for consumption behaviors, the literature reviewed reveals a complex relationship between caffeine and different variables, such as smoking, sleep and medication, which can interfere with the genetic predispositions. Furthermore, the current evidence is limited by a reliance on self-reported consumption data and a lack of genetic diversity in the groups studied. Ultimately, recognizing these genetic traits allows the scientific community to shift away from generic dietary guidelines and toward precision nutrition, using an individual’s DNA to optimize both safety and human performance when it comes to caffeine consumption.

REFERENCES:

1. Denden, S., Bouden, B., Haj Khelil, A., Ben Chibani, J., & Hamdaoui, M. H. (2016). Gender and ethnicity modify the association between the CYP1A2 rs762551 polymorphism and habitual coffee intake: evidence from a meta-analysis. Genetics and molecular research : GMR, 15(2), 10.4238/gmr.15027487. https://doi.org/10.4238/gmr.15027487

2. García, G., Ahluwalia, J., Candal-Pedreira, C., Teijeiro, A., Rey-Brandariz, J., Guerra-Tort, C., Mourino, N., Casal-Acción, B., Varela-Lema, L., & Pérez-Ríos, M. (2025). The prevalence and characterisation of energy drink consumption in North America: A systematic review. Public health, 242, 117–123. https://doi.org/10.1016/j.puhe.2025.02.035

3. Guest, N., Corey, P., Vescovi, J., & El-Sohemy, A. (2018). Caffeine, CYP1A2 Genotype, and Endurance Performance in Athletes. Medicine and science in sports and exercise, 50(8), 1570–1578. https://doi.org/10.1249/MSS.0000000000001596

4. Nehlig A. (2018). Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption. Pharmacological reviews, 70(2), 384–411. https://doi.org/10.1124/pr.117.014407

5. Rétey, J. V., Adam, M., Khatami, R., Luhmann, U. F., Jung, H. H., Berger, W., & Landolt, H. P. (2007). A genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep. Clinical pharmacology and therapeutics, 81(5), 692–698. https://doi.org/10.1038/sj.clpt.6100102